Russian CRO market expects to report yearly growth of 9.5% between 2009 and 2017

The Russian CRO market is set to emerge as a distinct competitor in the global CRO market, expected to report yearly growth of 9.5% between 2009 and 2017, according to a new report on companiesandmarkets.com. Growth is being driven by new Russian legislation (put in place during September 2010), which requires drug manufacturers to conduct trials within Russia before a product can be launched there.

Emerging Market for Clinical Trials in Russia - Curbs on New Drug Approval Timelines and Registration Fees Encourage the Emergence of a Major Global Player

The Russian CRO market is poised for considerable growth, attributed to new legislation brought in during September 2010, which requires that drug companies conduct clinical trials in Russia prior to registering new drugs there. Growth slowed between 2009 and 2010 as trial sponsors waited for legal changes before commencing work; 2011 is expected to follow the same pattern as they take effect.

Pharmaceutical companies see the Russian CRO market's potential, not least because of the speed at which study participants can be recruited and the high level of trial compliance. Prevalence of disease and population size also make Russia a viable alternative to other regions, and the number of trials sponsored by overseas companies has increased by 300% during the last ten years.

Oncology drugs account for 22% of the market, while respiratory, circulatory, endocrine and metabolic trials each hold a 14% share.